ANUHPHR vs NOVARTIND: Stock Comparison

Anuh Pharma Limited vs Novartis India Limited

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Novartis India Limited is the larger company by market capitalisation. Anuh Pharma Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Novartis India Limited shows faster revenue growth, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Anuh Pharma Limited and Novartis India Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, ANUHPHR is more favourable on 6 of 13 scored metrics and NOVARTIND on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
NOVARTIND is the larger company
₹4,062 Cr vs ₹793 Cr
P/E Ratio
ANUHPHR has a lower P/E
19.37x vs 41.85x
P/B Ratio
ANUHPHR has a lower P/B
2.26x vs 5x
EPS
NOVARTIND has higher earnings per share
₹37.76 vs ₹4.1
Dividend Yield
ANUHPHR has a higher dividend yield
1.87% vs 1.7%
Revenue Growth (TTM YoY)
NOVARTIND has faster revenue growth
8% vs 2%
EPS Growth (TTM YoY)
ANUHPHR has faster EPS growth
-6% vs -13.8%
Qtr Sales Growth
NOVARTIND has stronger quarterly sales growth
7.95% vs 2.01%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricANUHPHRNOVARTIND
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricANUHPHRNOVARTIND
Live Price₹79.07₹1,641.2
Day Change-0.48%-1.9%
Volume17,34254,369
52-Week High₹101.7₹1,780
52-Week Low₹67₹950
Distance from 52W High-22.25%-7.8%

Valuation

MetricANUHPHRNOVARTIND
Market Cap₹793 Cr₹4,062 Cr
P/E Ratio19.37x41.85x
P/B Ratio2.26x5x
EPS₹4.1₹37.76
Book Value₹35.28₹331.34
Dividend Yield1.87%1.7%

Growth

MetricANUHPHRNOVARTIND
Revenue Growth (TTM YoY)2%8%
EPS Growth (TTM YoY)-6%-13.8%
Qtr Sales Growth2.01%7.95%
Qtr Profit Growth-6.26%-13.8%

Profitability & Leverage

MetricANUHPHRNOVARTIND
ROE12.1%11.6%
ROCE15.9%16.2%
Net Margin5.32%26.3%
Operating Margin8%26.6%
Debt to Equity0x0x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricANUHPHRNOVARTIND
Promoter Holding71.78% 0.02 pp0%
FII Holding0.05% 0.05 pp0.17% 0.02 pp
DII Holding0%0.53% 0.11 pp
Public Holding28.16% 0.02 pp28.61% 0.11 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Anuh Pharma Limited and Novartis India Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.